A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo.
OBJECTIVE
To report a randomized, double-blind, placebo-controlled trial of an afternoon dose of the diuretic frusemide, used to establish an early evening diuresis and so diminish nocturnal voiding frequency and voided volume in elderly men presenting with lower urinary tract symptoms (LUTS).


METHODS
After a 2-week placebo run-in period, 49 men aged > 50 years were randomized to receive 40 mg of frusemide or placebo, taken 6 h before their usual bedtime. Day and night-time frequency and voided volume during the run-in and treatment periods were compared between the placebo and frusemide groups.


RESULTS
In the 43 men completing the study, there was a significant reduction in night-time frequency (-0.5 and 0) and percentage night-time voided volume (-18% and 0%) in those taking frusemide compared with placebo. Of patients on active treatment, seven of 19 had a reduction in night-time frequency of > or = 1, compared with only one of 20 on placebo, and 14 of 21 felt that frusemide had helped their nocturia, compared with only five of 22 on placebo.


CONCLUSIONS
Men with LUTS whose most prominent symptom is nocturia should complete a frequency-volume chart. In those with nocturnal polyuria, 40 mg of frusemide resulted in a significant reduction in night-time frequency and percentage voided volume.
Reynard
J M
JM
Department of Urology, The Royal London Hospital, UK.
Cannon
A
A
Yang
Q
Q
Abrams
P
P
D000368:Aged; D004232:Diuretics / Q000627:therapeutic use*; D004311:Double-Blind Method; D005665:Furosemide / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011141:Polyuria / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014554:Urination / Q000187:drug effects
D004232:Diuretics; D005665:Furosemide